The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review DOI Creative Commons
Chavdar S Pavlov, Daria Teplyuk, Л. Б. Лазебник

et al.

Terapevticheskii arkhiv, Journal Year: 2024, Volume and Issue: 96(4), P. 429 - 435

Published: May 2, 2024

In September 2023, the European Association for Study of Liver (EASL) updated disease nomenclature non-alcoholic (metabolically associated) fatty liver disease. The goals revision were to increase awareness among health care professionals, civil society and patients about disease, its course, treatment outcomes; combating stigma; focusing on initial etiological factor, including main (cardiometabolic) risk progression; improved diagnosis based biomarkers; positive impact potency search new drugs; ability provide personalized medical care. terms “non-alcoholic” “fatty” considered stigmatizing, therefore, it was proposed use term steatotic (SLD) as name this nosology. (NAFLD) or metabolic associated (MAFLD) have been replaced by dysfunction-associated (MASLD). case being combined with an alcohol a in which dysfunction is alcoholic referred MetALD. fundamental principle MASLD presence at least one cardiometabolic factors. Alcohol consumption interacts factors increases SLD decompensation. nonalcoholic steatohepatitis (NASH), according nomenclature, has (MASH). adoption should help course outcomes, well improve quality treatment.

Language: Английский

Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches DOI Creative Commons
Tatjana Radosavljević,

Milica Branković,

Janko Samardžić

et al.

Antioxidants, Journal Year: 2024, Volume and Issue: 13(8), P. 906 - 906

Published: July 26, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty (NAFLD), encompasses a range of conditions from steatosis to steatohepatitis (NASH). Its prevalence, especially among patients with metabolic syndrome, highlights its growing global impact. The pathogenesis MASLD involves dysregulation, inflammation, oxidative stress, genetic factors and, notably, mitochondrial dysfunction. Recent studies underscore the critical role dysfunction in MASLD's progression. Therapeutically, enhancing function has gained interest, along lifestyle changes and pharmacological interventions targeting processes. FDA's approval resmetirom for metabolic-associated (MASH) fibrosis marks significant step. While represents progress, further research is essential understand MASLD-related fully. Innovative strategies like gene editing small-molecule modulators, alongside interventions, can potentially improve treatment. Drug repurposing new targets will advance therapy, addressing increasing burden. Therefore, this review aims provide better understanding identify more effective preventive treatment strategies.

Language: Английский

Citations

14
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions DOI Open Access
Kyriazoula Chatzianagnostou, Melania Gaggini,

Adrian Suman Florentin

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 6218 - 6218

Published: June 5, 2024

Although good glycemic control in patients with type 2 diabetes (T2D) can prevent cardiovascular complications, many diabetic still have poor optimal control. A new class of antidiabetic drugs (e.g., glucagon-like peptide-1-GLP-1 receptor agonists, sodium-glucose co-transporters-SGLT2 inhibitors), addition to the low hypoglycemic effect, exert multiple beneficial effects at a metabolic and level, through mechanisms other than antihyperglycemic agents. This review aims discuss these drugs, highlighting benefits, description their action as well available data by preclinical clinical studies. Moreover, innovative tools T2D field will be described which may help advance towards better targeted personalized care future.

Language: Английский

Citations

9
Protective role of sulforaphane in lipid metabolism-related diseases DOI
Lingfeng Zhao, Jiahuan Li, Yiping Dang

et al.

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: Feb. 17, 2025

Language: Английский

Citations

1
The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis DOI Creative Commons

Qiong Lv,

Hua-Shan Zhao

Annals of Medicine, Journal Year: 2024, Volume and Issue: 56(1)

Published: Jan. 22, 2024

Objective While studies have documented how metabolic dysfunction-associated steatotic liver disease (MASLD) can contribute to cardiovascular (CVD), whether MASLD is associated with myocardial infarction (MI) remains debateable. Herein, we systematically reviewed published articles and performed a meta-analysis determine the relationship between MI risk.

Language: Английский

Citations

8
Secular trends in dental caries in Korean children and adolescents: 2007–2019 Korea National Health and Nutritional Examination Survey DOI Creative Commons
Yu‐Jin Kwon, So-Yoon Choi, Yaeji Lee

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 3, 2025

Dental caries is a common preventable childhood disease that has negative effects on physical, psychological, and social well-being. The present study was conducted to examine the secular trends in prevalence of dental among Korean children adolescents over time through subgroup analysis based age, sex, abdominal obesity, metabolic syndrome (MetS). This serial cross-sectional utilized representative data from Korea National Health Nutritional Examination Survey, covering period 2007 2019. participants included 9,702 aged between 10 18 years. A linear-by-linear association test performed evaluate trend according subgroups. mean significantly decreased both boys girls during (all p-values for < 0.001). These were consistent across different age subgroups: 10–12, 13–15, 16–18 In analysis, normal-weight However, no significant decrease observed overweight or obese groups either sex. Importantly, did not subgroups with obesity MetS. non-abdominal group, showed 0.001), while only (p-value = 0.027). No group girls. Similarly, non-MetS MetS sexes. past 13 years adolescents. overweight, MetS, caries.

Language: Английский

Citations

0
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease DOI
Bryan Adrián Priego-Parra, Rocío Gallego‐Durán, Berenice M Román-Calleja

et al.

Trends in Endocrinology and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Mitochondrial Dysfunction as a Pathogenesis and Therapeutic Strategy for Metabolic-Dysfunction-Associated Steatotic Liver Disease DOI Open Access

Xiangqiong Li,

Wenling Chen, Zhuangzhuang Jia

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4256 - 4256

Published: April 30, 2025

Metabolic-dysfunction-associated steatotic liver disease (MASLD) has emerged as a significant public health concern, attributed to its increasing prevalence and correlation with metabolic disorders, including obesity type 2 diabetes. Recent research highlighted that mitochondrial dysfunction can result in the accumulation of lipids non-adipose tissues, well increased oxidative stress inflammation. These factors are crucial advancing progression MASLD. Despite advances understanding MASLD pathophysiology, challenges remain identifying effective therapeutic strategies targeting dysfunction. This review aims consolidate current knowledge on how imbalance affects development MASLD, while addressing existing gaps potential avenues for future research. was conducted after systematic search comprehensive academic databases such PubMed, Embase, Web Science gather information mitochondrial-based treatments

Language: Английский

Citations

0
High-fat diet restriction to adult male mice maintains normal body weight but leads to liver impairment by disrupting mitochondrial oxidative phosphorylation DOI
Chun‐Hsien Chiang, Pu‐Sheng Hsu, Shau‐Ping Lin

et al.

The Journal of Nutritional Biochemistry, Journal Year: 2025, Volume and Issue: unknown, P. 109941 - 109941

Published: April 1, 2025

Language: Английский

Citations

0
Taraxasterol from Dandelion Prevents Glucolipid Metabolism Dysregulation in Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease by Activating the Fxr Signaling Pathway DOI

Shanxia Xu,

Tingting Li,

Guang-yi Liao

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
Liquiritin Ameliorates Palmitic Acid‐Induced Hepatic Steatosis in Mouse Primary Hepatocytes by Suppressing the VEGFA Signaling Pathway DOI Creative Commons
Qi Zhang, Yan Wang,

Xiong Qingfang

et al.

Journal of Food Biochemistry, Journal Year: 2025, Volume and Issue: 2025(1)

Published: Jan. 1, 2025

Nonalcoholic fatty liver disease (NAFLD) has become a global pandemic, imposing significant socioeconomic burden. Hepatic steatosis is key pathological event in NAFLD. However, there still lack of effective drugs for NAFLD treatment. Liquiritin (LIQ), derived from licorice root, exhibits antioxidative and anti‐inflammatory properties, making it valuable managing various conditions such as dermatological disorders, respiratory ailments, gastritis. Here, we investigated the impact underlying mechanisms LIQ on hepatic mouse primary hepatocytes (MPHs). Our study found that significantly decreased palmitic acid (PA)‐induced lipid accumulation MPHs. Additionally, remarkably increased mRNA expression Cpt1a, PPAR α , Ehhadh, Cyp4a10, Acox1, suggesting achieves its lipid‐lowering effect by regulating mitochondria‐mediated β‐oxidation. Furthermore, regulatory mitochondrial oxidative phosphorylation (OXPHOS) process was confirmed Seahorse analysis. Mechanistically, bioinformatics analysis predicted VEGFA crucial target mediating beneficial effects against PA‐induced Notably, treatment with purified protein partially counteracted properties LIQ. our data showed promoted degradation through ubiquitin–proteasome pathway. Therefore, findings not only confirm MPHs but also identify potential target. These results highlight therapeutic promise introduce novel treating steatosis.

Language: Английский

Citations

0